secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001193125-26-039409
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M
--------------------------------------------------------------------------------

- Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.
- MRD segment achieved positive Adjusted EBITDA and cash flow; MRD revenue Q4 $61.9M (+54%), FY $212.3M (+46%).
- clonoSEQ test volume Q4 30,038 (+43% YoY); FY 105,587 (+39% YoY); expanded Medicare coverage in mantle cell lymphoma.
- Signed two non-exclusive immune receptor data licensing agreements with Pfizer.
- FY2026 guidance: MRD revenue $255-265M; total OpEx $350-360M; management expects company-wide profitability in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/0001193125-26-039409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/adpt-20260205.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-039409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer